Several biologic therapies targeting IL17 and/or its receptor have been approved for psoriasis treatment, including monoclonal antibodies such as secukinumab and ixekizumab targeting IL17A, brodalumab targeting the IL17 receptor, bimekizumab which inhibits both IL17A and IL17F, and finally the nanobody sonelokimab targeting IL17 isoforms, demonstrating significant clinical efficacy [9–14]. Here, IL17A is linked to psoriasis.